PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

Conditions

• Diffuse Midline Glioma
• Diffuse Midline High-grade Glioma
• Ependymoma
• Medulloblastoma

Eligibility Criteria

Sex

ALL

Age

4 Years - 25 Years

Healthy Volunteers

Not accepted

Interventions

• PEP-CMV vaccine — BIOLOGICAL
  Intra-dermally administered half in the RIGHT groin and half in the LEFT groin.
• Tetanus booster — BIOLOGICAL
  Td 5 flocculation units, Lf
• Nivolumab — BIOLOGICAL
  Administered intravenously
• Temozolomide — DRUG
  Administered orally

Study Details

This is a multisite, phase I/II clinical trial in children and young adults with newly-diagnosed high-grade glioma (HGG), diffuse midline glioma (DMG) and recurrent HGG/DMG, Medulloblastoma (MB), or ependymoma (EPN) to determine the safety, immunogenicity, and efficacy of a CMV-directed peptide vaccine plus checkpoint blockade.

Key Dates

Start date

Jun 30, 2026

Status verified

Jun 2026

Primary completion

Aug 31, 2031

Completion

Jun 30, 2051

Study Design

Enrollment

68 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Phase I Stratum I: Temozolomide + Nivolumab + PEP-CMV vaccine + Td booster
  Patients with newly-diagnosed high-grade glioma or DMG may be enrolled any time within 42 days after completing radiation. Cycle 1 (Induction cycle) is 77±2 days. Will receive 1 course of temozolomide 200 mg/m\^2/day x 5 days on Days 1-5 of cycle 1 \& receive PEP-CMV vaccine at dose level 1 (250 μg/m\^2) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days until recurrence/progression (up to 10 years). Patients 18 and older will receive a tetanus (Td) booster at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine delivered 6-24 hours prior to the first vaccine on day 21. Patients will also receive nivolumab 3 mg/kg IV on day 14±1 day then every 14 days ±2 days thereafter.
• Experimental: Phase I Stratum II: Temozolomide + Nivolumab + PEP-CMV vaccine + Td booster
  Patients with recurrent/progressive HGG or DMG with measurable disease can be enrolled at any point following recurrence regardless of any prior therapy. Cycle 1 (Induction cycle) is 77±2 days. Will receive 1 course of temozolomide 200 mg/m\^2/day x 5 days on Days 1-5 of cycle 1 \& receive PEP-CMV vaccine at dose level 1 (250 μg/m\^2) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days until recurrence/progression (up to 10 years). Patients 18 and older will receive a tetanus (Td) booster at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine delivered 6-24 hours prior to the first vaccine on day 21. Patients will also receive nivolumab 3 mg/kg IV on day 14±1 day then every 14 days ±2 days thereafter.
• Experimental: Phase I Stratum III: Temozolomide + Nivolumab + PEP-CMV vaccine + Td booster
  Patients with recurrent/progressive MB or EPN with measurable disease can be enrolled at any point following recurrence regardless of any prior therapy. Cycle 1 (Induction cycle) is 77±2 days. Will receive 1 course of temozolomide 200 mg/m\^2/day x 5 days on Days 1-5 of cycle 1 \& receive PEP-CMV vaccine at dose level 1 (250 μg/m\^2) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days until recurrence/progression (up to 10 years). Patients 18 and older will receive a tetanus (Td) booster at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine delivered 6-24 hours prior to the first vaccine on day 21. Patients will also receive nivolumab 3 mg/kg IV on day 14±1 day then every 14 days ±2 days thereafter.
• Experimental: Phase II: Temozolomide + Nivolumab + PEP-CMV vaccine + Td booster
  Cycle 1 (Induction cycle) is 77±2 days. Will receive 1 course of temozolomide 200 mg/m\^2/day x 5 days on Days 1-5 of cycle 1 \& receive PEP-CMV vaccine at dose level 1 (250 μg/m\^2) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days until recurrence/progression. Patients 18 and older will receive a tetanus (Td) booster at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine delivered 6-24 hours prior to the first vaccine on day 21. Patients will also receive nivolumab 3 mg/kg IV on day 14±1 day then every 14 days ±2 days thereafter.

Primary Outcome Measure

Proportion of patients with unacceptable toxicity [ Time Frame: From the first vaccine (day 21) through 2 weeks after the third vaccine (day 49) (estimated to be 42 days) ]

Central Contacts

• Eric M Thompson, M.D.
  314-454-2810
  [email protected]

Locations (3)

Find similar trials in St Louis, MO

Related Studies

• LET Optimized IMPT in Treating Pediatric Patients With Ependymoma
  PHASE1 · Recruiting · M.D. Anderson Cancer Center · Boston, Massachusetts
• DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
  PHASE2 · Recruiting · Giselle Sholler · Little Rock, Arkansas
• Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
  Recruiting · University of California, San Francisco · Los Angeles, California
• Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
  PHASE2 · Recruiting · St. Jude Children's Research Hospital · Palo Alto, California